NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 852.00K | 782.00K | 812.00K | 695.00K | 407.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.48M | 1.29M | 1.32M | 920.00K | 716.00K |
| Operating Income | -1.48M | -1.29M | -1.32M | -920.00K | -716.00K |
| Income Before Tax | -1.55M | -1.25M | -1.33M | -922.00K | -737.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.55M | -1.25M | -1.33M | -922.00K | -737.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.55M | -1.25M | -1.33M | -922.00K | -737.00K |
| EBIT | -1.48M | -1.29M | -1.32M | -920.00K | -716.00K |
| EBITDA | -1.47M | -1.27M | -1.31M | -905.00K | -713.00K |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 71.08M | 63.53M | 61.49M | 56.53M | 48.29M |
| Average Diluted Shares Outstanding | 71.08M | 63.53M | 61.49M | 56.53M | 48.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |